Taken together, these results showed that the transcriptomes in MSCsBM and MSCsPP differed, which hint that the most differentially expressed gene, IL‐22, likely explains, to some degree, the difference in the therapeutic potential of MSCsBM and MSCsPP with respect to murine IBD. This evidence concerns the gene IL22 and inflammatory bowel disease.